Update shared on25 Sep 2025
Fair value Increased 7.47%The upward revision in MedinCell's price target reflects a significant increase in consensus revenue growth forecasts coupled with a notable decline in the future P/E ratio, resulting in a new fair value estimate of €24.47.
What's in the News
- UZEDY, a long-acting injectable risperidone for schizophrenia, received regulatory approval in South Korea and will be distributed by Teva Handok.
- UZEDY demonstrated strong commercial performance, with $117 million in net sales in 2024 and $95 million in the first half of 2025.
- MedinCell receives mid- to high-single digit royalties on all worldwide UZEDY sales and is eligible for up to $105 million in commercial milestone payments.
Valuation Changes
Summary of Valuation Changes for MedinCell
- The Consensus Analyst Price Target has risen from €22.77 to €24.47.
- The Consensus Revenue Growth forecasts for MedinCell has significantly risen from 54.8% per annum to 69.8% per annum.
- The Future P/E for MedinCell has significantly fallen from 18.66x to 16.71x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.